Get the Stockscreener App
68.24
0.22%
-0.15
Halozyme Therapeutics Inc stock is traded at $68.24, with a volume of 11.68M.
It is down -0.22% in the last 24 hours and up +3.36% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$68.39
Open:
$69.02
24h Volume:
11.68M
Relative Volume:
5.40
Market Cap:
$7.98B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
22.60
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+4.68%
1M Performance:
+3.36%
6M Performance:
-2.71%
1Y Performance:
+14.40%
1-Day Range:
$67.52
$70.00
1-Week Range:
$64.72
$70.50
52-Week Range:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.24 | 8.04B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Aug-06-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-10-25 | Resumed | Goldman | Neutral |
| May-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Downgrade | Leerink Partners | Market Perform → Underperform |
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Latham & Watkins Advises on Halozyme Therapeutics’ Convertible Senior Notes Offerings Totaling US$1.3 Billion - Legal Desire Media and Insights
Halozyme Therapeutics down after $1.3 bln convertible bonds sale - TradingView
How Halozyme Therapeutics Inc. (RV7) stock behaves in tightening cyclesTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Will Halozyme Therapeutics Inc. stock benefit from upcoming earnings reportsMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Halozyme Announces Pricing of $1.3 Billion in Notes - TipRanks
Halozyme (HALO): FDA approves DARZALEX Faspro, first and only HR-SMM therapy - Stock Titan
Halozyme Therapeutics, Inc. Announces Pricing of Convertible Senior Notes - TradingView
[8-K] HALOZYME THERAPEUTICS, INC. Reports Material Event | HALO SEC FilingForm 8-K - Stock Titan
Developing predictive dashboards with Halozyme Therapeutics Inc. dataMarket Growth Review & Community Consensus Trade Signals - newser.com
How Halozyme Therapeutics Inc. (RV7) stock reacts to stronger dollarGold Moves & Smart Swing Trading Techniques - newser.com
Halozyme Therapeutics Prices $1.3 Billion Private Debt Offering - MarketScreener
Halozyme prices $1.3 billion convertible notes offering By Investing.com - Investing.com Nigeria
Halozyme raises 2025 guidance to $1.3B–$1.375B revenue driven by royalty momentum and expands with Elektrofi acquisition - MSN
Exit strategy if you’re trapped in Halozyme Therapeutics Inc.July 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Halozyme Therapeutics prices $1.3 billion convertible notes - MSN
Will Halozyme Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Update & Daily Price Action Insights - newser.com
Halozyme (NASDAQ: HALO) prices $1.3B convertibles; $87.20 conversion price - Stock Titan
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 - PR Newswire
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Will Halozyme Therapeutics Inc. price bounce be sustainableJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Understanding Momentum Shifts in (HALO) - news.stocktradersdaily.com
Why Halozyme Therapeutics Inc. stock is in analyst buy zoneWeekly Profit Recap & Real-Time Stock Price Movement Reports - newser.com
Is Halozyme Therapeutics Inc. (RV7) stock dividend growth reliable2025 Institutional Moves & Verified Entry Point Signals - newser.com
Halozyme announces $1.3 billion convertible notes offering By Investing.com - Investing.com Australia
Halozyme Therapeutics, Inc. (HALO.MX) stock price, news, quote and history - Yahoo Finance UK
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st
Published on: 2025-11-06 04:53:41 - newser.com
Halozyme Extends Credit Facility and Increases Commitments - MSN
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersWeekly Market Outlook & Low Volatility Stock Recommendations - newser.com
Why Halozyme Therapeutics Inc. (RV7) stock is favored by hedge funds2025 Macro Impact & Risk Controlled Daily Trade Plans - fcp.pa.gov.br
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2025 Earnings Call Transcript - Insider Monkey
What insider trading reveals about Halozyme Therapeutics Inc. stockWeekly Investment Summary & Growth Oriented Trade Recommendations - newser.com
Tools to assess Halozyme Therapeutics Inc.’s risk profileFed Meeting & Weekly High Return Stock Forecasts - newser.com
Will Halozyme Therapeutics Inc. stock see PE expansionEarnings Overview Report & Risk Controlled Daily Trade Plans - newser.com
Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 - MSN
Can Halozyme Therapeutics Inc. stock continue upward trendDividend Hike & Safe Capital Growth Stock Tips - newser.com
Why Halozyme Therapeutics Inc. stock could be next big winner2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look - AOL.com
Renaissance Group Bets $35M on Halozyme’s Subcutaneous Drug Delivery Disruption - NAI500
Halozyme Therapeutics IncExpects Option fo - 富途牛牛
Halozyme Therapeutics (HALO): Exploring the Latest Valuation After Recent Strong Share Price Performance - Yahoo Finance
Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look - The Motley Fool
Halozyme (HALO) Plans to Issue $1.3 Billion in Convertible Notes - GuruFocus
Halozyme Therapeutics, Inc. and Halozyme, Inc. Enters into an Amendment No. 3 of Credit Agreement - MarketScreener
Should you hold or exit Halozyme Therapeutics Inc. nowPortfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
Halozyme Therapeutics dips after unveiling $1.3 bln convertible bonds sales - TradingView
Halozyme announces $1.3 billion convertible notes offering - Investing.com
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 - MarketScreener
What Recent Analyst Updates Mean for the Evolving Story at Halozyme Therapeutics - Yahoo Finance
Why analysts upgrade Halozyme Therapeutics Inc. stockInflation Watch & AI Enhanced Trading Signals - fcp.pa.gov.br
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):